Bausch + Lomb Corporation $BLCO Shares Purchased by Trexquant Investment LP

Trexquant Investment LP grew its stake in Bausch + Lomb Corporation (NYSE:BLCO) by 5.8% during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 20,255 shares of the company’s stock after purchasing an additional 1,108 shares during the quarter. Trexquant Investment LP’s holdings in Bausch + Lomb were worth $294,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. Deutsche Bank AG acquired a new stake in Bausch + Lomb during the first quarter worth about $50,750,000. Allianz Asset Management GmbH bought a new position in shares of Bausch + Lomb in the first quarter valued at approximately $4,712,000. Alberta Investment Management Corp boosted its holdings in shares of Bausch + Lomb by 8.6% in the first quarter. Alberta Investment Management Corp now owns 3,266,193 shares of the company’s stock valued at $47,360,000 after acquiring an additional 258,000 shares in the last quarter. Tang Capital Management LLC boosted its holdings in Bausch + Lomb by 28.6% during the fourth quarter. Tang Capital Management LLC now owns 450,000 shares of the company’s stock worth $8,127,000 after buying an additional 100,000 shares in the last quarter. Finally, Landscape Capital Management L.L.C. bought a new stake in Bausch + Lomb during the first quarter worth approximately $1,450,000. Institutional investors and hedge funds own 11.07% of the company’s stock.

Bausch + Lomb Stock Down 1.3%

Shares of NYSE:BLCO opened at $15.33 on Wednesday. The company has a debt-to-equity ratio of 0.76, a quick ratio of 0.98 and a current ratio of 1.55. The company has a market cap of $5.43 billion, a PE ratio of -19.65, a price-to-earnings-growth ratio of 1.58 and a beta of 0.63. Bausch + Lomb Corporation has a 52 week low of $10.45 and a 52 week high of $21.69. The firm has a 50 day simple moving average of $14.24 and a 200 day simple moving average of $13.44.

Bausch + Lomb (NYSE:BLCO) last released its earnings results on Wednesday, July 30th. The company reported $0.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.06 by $0.01. Bausch + Lomb had a negative net margin of 5.58% and a positive return on equity of 2.33%. The company had revenue of $1.28 billion during the quarter, compared to the consensus estimate of $1.25 billion. During the same quarter in the prior year, the firm earned $0.13 EPS. The company’s revenue was up 5.1% compared to the same quarter last year. Bausch + Lomb has set its FY 2025 guidance at EPS. As a group, research analysts expect that Bausch + Lomb Corporation will post 0.74 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. Barclays reduced their target price on shares of Bausch + Lomb from $19.00 to $16.00 and set an “equal weight” rating for the company in a report on Monday, June 9th. Citigroup raised their target price on shares of Bausch + Lomb from $13.00 to $15.00 and gave the stock a “neutral” rating in a report on Wednesday, July 9th. Evercore ISI raised their target price on shares of Bausch + Lomb from $15.50 to $16.00 and gave the stock an “outperform” rating in a report on Tuesday, July 8th. HC Wainwright raised their target price on shares of Bausch + Lomb from $15.00 to $16.00 and gave the stock a “buy” rating in a report on Thursday, July 31st. Finally, Morgan Stanley upped their price target on shares of Bausch + Lomb from $12.00 to $13.00 and gave the company an “equal weight” rating in a research report on Friday, August 1st. Three analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Bausch + Lomb currently has an average rating of “Hold” and an average price target of $15.56.

Bausch + Lomb Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.